Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Fungal and Parasitic Infections

Interleukin-6 Deficiency Influences Cytokine Expression in Susceptible BALB Mice Infected with Leishmania major but Does Not Alter the Outcome of Disease

Richard G. Titus, Gregory K. DeKrey, Robin V. Morris, Milena B. P. Soares
Richard G. Titus
Departments of Pathology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory K. DeKrey
Environmental Health, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523-1671, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin V. Morris
Departments of Pathology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Milena B. P. Soares
Centro de Pesquisas Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador-Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.69.8.5189-5192.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Since interleukin-6 (IL-6) may promote Th2 responses, we infected BALB IL-6-deficient (IL-6−/−) mice with Leishmania major. There was not a significant difference between the courses of infection (lesion size and parasite burden) in IL-6−/− and wild-type mice, but IL-6−/−mice expressed lower levels of Th2- and Th1-associated cytokines.

Perhaps the best-studied example of a disease in which Th1 and Th2 cells dictate the outcome of the infection is cutaneous leishmaniasis induced by Leishmania major. Mice that develop a Th1 response to infection with L. major (e.g., C57BL/6 mice) recover from their infections, whereas mice that develop a Th2 response (e.g., BALB/c mice) succumb to infection (reviewed in references 3, 10, 16, and18). Among the many regulators of Th development, it has been suggested that interleukin-6 (IL-6) favors the outgrowth of Th2 cells (19). Several cell types, including macrophages, dendritic cells, and T cells, produce IL-6. Originally thought of as a B-cell growth factor, IL-6 is now known to have effects on several components of the immune system (1, 24).

Work by Moskowitz et al. (15) showed that C57BL/6 IL-6−/− and wild-type C57BL/6 mice recovered from infections with L. major with the same kinetics. However, since C57BL/6 mice do not develop a Th2 response when infected with L. major, these experiments did not address the question of whether IL-6 is involved in Th2 development against infection with L. major. To address this question, it is necessary to investigate the role of IL-6 in the development of an anti-L. major Th2 response in susceptible BALB mice.

The course of infection with L. major in IL-6−/− BALB.B mice does not significantly differ from the course of infection in susceptible wild-type BALB.B mice.In pilot experiments, we determined whether the amounts of IL-6 produced by susceptible and resistant mice differed. We utilized an in vitro priming system, which we have previously reported mimics the in vivo response to L. major (23). In this system, we found that cells from susceptible mice produced between two- and fourfold more IL-6 than cells from resistant mice.

Because this result suggested that IL-6 secretion correlates with susceptibility to infection with L. major, we hypothesized that IL-6−/− BALB.B mice (6) (BALB.B/AiTac-[KO]IL-6 N9; Taconic Farms, Germantown, N.Y.) would be more resistant to infection with L. major than susceptible wild-type BALB.B mice (C.B10-H2b/LilMcdJ [BALB.B10]; Jackson Laboratories, Bar Harbor, Maine). BALB.B mice (as well as other BALB congenics, such as BALB.K) are as susceptible to infection with L. major as BALB/c mice are; all of the mice die from infection at the same time postinfection (4). Groups of five mice each were infected subcutaneously with 2 × 106L. major promastigotes (LV39) in one hind footpad. The lesion progression and parasite burden were monitored as described elsewhere (11, 23). Contrary to our hypothesis, the lesion size (Fig. 1) in IL-6−/− BALB.B mice was not significantly different from that seen in wild-type susceptible BALB.B mice (three-way analysis of variance followed by all pairwise multiple-comparison posthoc t tests [Student-Newman-Keuls method]; differences were considered significant at a P of <0.05). However, the lesion size did not fully reflect the extent of pathology in these experiments. In the three replicate experiments performed, the pathology associated with infection in the IL-6−/− mice was consistently more severe than that in control BALB.B mice. That is, lesions on IL-6−/− mice ulcerated and became necrotic more rapidly (5 to 7 days earlier) than those on control BALB.B mice.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

The course of infection with L. major in susceptible BALB.B mice does not significantly differ from the course of infection in IL-6−/− BALB.B mice. The results shown are averages of three independent experiments ± standard errors of the mean. KO, knockout.

To attempt to confirm the results shown in Fig. 1, and because lesion pathology and parasite burden within lesions do not always correlate (11), we also determined the numbers of parasites in the lesions of infected BALB.B and IL-6−/− BALB.B mice by using published techniques (11). IL-6−/− BALB.B mice had somewhat fewer parasites within their lesions at all times tested; however, these differences were not statistically significant (Fig. 1). Taken as a whole, the data showed small differences (both positive and negative) between the susceptibilities of IL-6−/− mice and control BALB.B mice to infection with L. major. However, none of these differences was statistically significant.

IL-6 deficiency down regulates the expression of both Th1- and Th2-associated cytokines in BALB.B mice infected with L. major.In an effort to explain the mechanism underlying the lack of effect of IL-6 on susceptibility to infection with L. major, we measured the expression of mRNA for five different cytokines involved in the immune response to the parasite. We measured IL-4 and IL-13 mRNA levels, since these cytokines drive Th2 responses (3, 10, 12, 18). We measured IL-12 and gamma interferon (IFN-γ) mRNA levels, since these factors are critical for the development of a Th1 response and the subsequent destruction ofL. major (3, 10, 18). Finally, we also measured levels of IL-10 mRNA expression, since IL-10, IL-12, and IFN-γ cross regulate each other's expression (3, 10, 14, 18, 23).

Two mice per experimental group were killed, and lesion-draining popliteal and inguinal lymph nodes were removed and processed using published techniques (13). There was no difference in lymph node size between groups (data not shown). Competitors and primers for mouse β-actin, IL-4, IL-10, IL-12, and IFN-γ were generated according to published procedures (13, 17). A competitor for mouse IL-13 was constructed in our laboratory by PCR using primers (CGCTGGCGGGTTCTGTGTACTGGATGGAGGCGGATAAAGTTG and GCCTCTC CCCAGCAAAGTCTCTACGATACGGGAGGGCTTACC AT) and the pCRII-TOPO plasmid (Invitrogen Corp., Carlsbad, Calif.) as the template DNA. IL-13 primers (CGCTGGCGGGTTCTGTGTA and GCCTCTCCCCAGCAAAGTCT) and all other primers (13, 17) were purchased from Gibco BRL, Life Technologies, Inc. (Rockville, Md.).

Fluorescent-band intensities were determined as peak heights for each lane of agarose gels using the 1D-Multi function of AlphaEase image analysis software, version 5 (Alpha Innotech, San Leandro, Calif.). The ratio of peak heights for competitor and cDNA bands was plotted against the number of competitor molecules added per reaction on a log-log scale, and the coefficients of a least-squares regression line were calculated using SigmaPlot graphical software version 5 for Windows (SPSS Inc., Chicago, Ill.). The number of specific cDNA molecules per reaction equals antilog (−intercept/slope).

First, it should be mentioned that baseline and spontaneous production of all cytokines measured did not differ (P > 0.05) between uninfected control BALB.B and IL-6−/−BALB.B mice except for IFN-γ. Baseline expression of IFN-γ in IL-6−/− BALB.B mice was 69% of that seen in BALB.B mice (P = 0.047). Therefore, for IFN-γ mRNA expression, the results are normalized to the average uninfected IFN-γ levels for each mouse strain.

In Fig. 2, the data from three replicate experiments have been normalized and are presented as the fold difference of the IL-6−/− group compared to the control. This approach allowed for a statistical analysis of all experiments, and P values are presented in the figure. IL-6 deficiency led to depressed expression of all mRNAs analyzed except that of IFN-γ.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Expression of cytokine mRNA in lesion-draining lymph nodes. mRNA levels are shown for wild-type (●) and IL-6−/− (■) mice relative to wild-type mice on day 7. The data represent the mean ± standard error of the mean for three independent experiments. Values of P are shown for the treatment factor (wild-type versus IL-6 deficient) from a three-way analysis of variance in which the three factors were treatment, day, and experimental trial.

Finally, it should be noted that we also measured IL-6 mRNA expression levels in IL-6−/− and control BALB.B mice and that IL-6 mRNA could not be detected in BALB.B IL-6−/− mice.

Our results agree with those of Moskowitz et al. (15), who showed that IL-6 had little effect in resistant C57BL/6 mice infected with L. major. They also agree with those of Saha et al. (20), who showed that treatment with an anti-IL-6 antibody was therapeutic for susceptible BALB/c mice infected with L. major; however, as was the case in this study using IL-6-deficient mice (Fig. 1), it did not cause the animals to recover from their infections. Therefore, IL-6 can be involved in the development of a Th2 response in susceptible BALB/c mice infected with L. major;however, IL-6 is not required for the development of that response. Alternatively, since it has been suggested that the Th2 response seen in BALB/c mice infected with L. major results from cross-reactivity with an environmental antigen(s) (5), the results presented here may suggest that IL-6 is not required for the maintenance of a Th2 response to L. major.

It is interesting that in BALB.B IL-6−/− mice infected with L. major, the levels of expression of mRNA for both Th1- and Th2-associated cytokines (except IFN-γ) were reduced (Fig. 2). This pattern of cytokine response is not unique. For example, IL-6−/− mice have been reported to produce lower levels of IL-4 but unchanged levels of IFN-γ in other experimental settings (2, 25). The results presented here are also in partial agreement with those of Saha et al. (20), who showed that treating BALB/c mice with an anti-IL-6 antibody lowered production of IL-4 (as was the case here [Fig. 2]) but increased production of IFN-γ (while IFN-γ mRNA expression was unchanged or slightly elevated here [Fig. 2]). This discrepancy may be due to the different systems analyzed. Therefore, in the BALB.B IL-6−/− mouse system examined here, IL-6 deficiency appeared to generally lower the set point for the expression of both Th1 and Th2 cytokines but not their overall balance of expression. As a result, BALB.B IL-6−/− mice remained susceptible to infection with L. major.

Others have also reported that IL-6 can affect the development of both type 1 and type 2 immune responses. The literature regarding the effect of IL-6 on the development of immune responses is large; however, representative examples of the diverse effects of IL-6 include the following: (i) IL-6 is required for the development of a Th1 response (26), (ii) IL-6 is required for the development of a Th2 response (19), and (iii) IL-6 is required for the development of both a Th1 and Th2 response (21).

Although IL-6 is not required for the development of either a Th1 or a Th2 response in mice infected with L. major, it can affect the immune responses to other pathogens, albeit variably. IL-6 is not required for the development of a Th2 response in mice infected withSchistosoma mansoni, but it has an important regulatory role (8, 9). In one study, IL-6 appeared to be critical for the development of resistance of mice to Mycobacterium tuberculosis (an infection in which a type 1 response leads to resistance [7]), but in another study IL-6 was not essential for the development of immunity to M. tuberculosis(22). Finally, IL-6 can also compromise the ability of mice to resist viral infection (6).

In summary, IL-6 deficiency reduces the expression of both Th1- and Th2-associated cytokines in BALB mice infected with L. major, but it does not alter the susceptible phenotype of the mice. Indeed, taking the results presented here in conjunction with the results of others, it appears that the effect that IL-6 may have on the development of either a Th1 or Th2 response cannot be predicted. Rather, each experimental system must be examined on a case-by-case basis.

ACKNOWLEDGMENTS

This work was supported by NIH grant AI-29955.

Notes

Editor: J. M. Mansfield

FOOTNOTES

    • Received 19 March 2001.
    • Returned for modification 12 April 2001.
    • Accepted 2 May 2001.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Akira S.,
    2. Taga T.,
    3. Kishimoto T.
    Interleukin-6 in biology and medicine.Adv. Immunol.541993178
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Anguita J.,
    2. Rincon M.,
    3. Samanta S.,
    4. Barthold S. W.,
    5. Flavell R. A.,
    6. Fikrig E.
    Borrelia burgdorferi-infected, interleukin-6-deficient mice have decreased Th2 responses and increased Lyme arthritis.J. Infect. Dis.178199815121515
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bogdan C.,
    2. Rollinghoff M.
    The immune response to Leishmania: mechanisms of parasite control and evasion.Int. J. Parasitol.281998121134
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Howard J. G.,
    2. Hale C.,
    3. Chan-Liew W. L.
    Immunological regulation of experimental cutaneous leishmaniasis. 1. Immunogenetic aspects of susceptibility to Leishmania tropica in mice.Parasite Immunol.21980303314
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Julia V.,
    2. McSorley S. S.,
    3. Malherbe L.,
    4. Breittmayer J.-P.,
    5. Girard-Pipau F.,
    6. Beck A.,
    7. Glaichenhaus N.
    Priming by microbial antigens from the intestinal flora determines the ability of CD4+ T cells to rapidly secrete IL-4 in BALB/c mice infected with Leishmania major.J. Immunol.165200056375645
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Kopf M.,
    2. Baumann H.,
    3. Freer G.,
    4. Fruedenberg M.,
    5. Lamers M.,
    6. Kishimoto T.,
    7. Zinkernagel R.,
    8. Bluethmann H.,
    9. Kohler G.
    Impaired immune and acute-phase responses in interleukin-6-deficient mice.Nature3681994339342
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Ladel C. H.,
    2. Blum C.,
    3. Dreher A.,
    4. Reifenberg K.,
    5. Kopf M.,
    6. Kaufmann S. H. E.
    Lethal tuberculosis in interleukin-6-deficient mutant mice.Infect. Immun.65199748434849
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. La Flamme A. C.,
    2. MacDonald A. S.,
    3. Pearce E. J.
    Role of IL-6 in directing the initial immune response to schistosome eggs.J. Immunol.164200024192426
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. La Flamme A. C.,
    2. Pearce E. J.
    The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferative, IL-2 receptor expression, and B cell responses.J. Immunol.162199958295837
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Launois P.,
    2. Tacchini-Cottier F.,
    3. Parra-Lopez C.,
    4. Louis J. A.
    Cytokines in parasitic diseases: the example of cutaneous leishmaniasis.Int. Rev. Immunol.171998157180
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Lima H. C.,
    2. Bleyenberg J.,
    3. Titus R. G.
    A simple method for quantifying Leishmania in tissues of infected animals.Parasitol. Today1319978082
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Matthews D. J.,
    2. Emson C. L.,
    3. McKenzie G. L.,
    4. Jolin H. E.,
    5. Blackwell J. M.,
    6. McKenzie A. N.
    IL-13 is a susceptibility factor for Leishmania major infection.J. Immunol.164200014581462
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Mbow M. L.,
    2. Bleyenberg J. A.,
    3. Hall L. R.,
    4. Titus R. G.
    Phlebotomus papatasi sand fly salivary gland lysate downregulates a Th1, but upregulates a Th2, response in mice infected with Leishmania major.J. Immunol.161199855715577
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Morris S. C.,
    2. Madden K. B.,
    3. Adamovicz J. J.,
    4. Gause W. C.,
    5. Hubbard B. R.,
    6. Gately M. K.,
    7. Finkelman F. D.
    Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection.J. Immunol.152199410471056
    OpenUrlAbstract
  15. 15.↵
    1. Moskowitz N. H.,
    2. Brown D. R.,
    3. Reiner S. L.
    Efficient immunity against Leishmania major in the absence of interleukin-6.Infect. Immun.65199724482450
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Mosmann T. R.,
    2. Coffman R. L.
    Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties.Annu. Rev. Immunol.71989145173
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Platzer C.,
    2. Richter G.,
    3. Überla K.,
    4. Müller W.,
    5. Blöcker H.,
    6. Diamantstein T.,
    7. Blankenstein T.
    Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction.Eur. J. Immunol.22199211791184
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Reiner S. L.,
    2. Locksley R. M.
    The regulation of immunity to Leishmania major.Annu. Rev. Immunol.131995151177
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Rincon M.,
    2. Anguita J.,
    3. Nakamura T.,
    4. Fikrig E.,
    5. Flavell R. A.
    Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells.J. Exp. Med.1851997461469
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Saha B.,
    2. Saini A.,
    3. Germond R.,
    4. Perrin P. J.,
    5. Harlan D. M.,
    6. Davis T. A.
    Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF.Eur. J. Immunol.29199923192329
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Samoilova E. B.,
    2. Horton J. L.,
    3. Hilliard B.,
    4. Liu T. S.,
    5. Chen Y.
    IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells.J. Immunol.161199864806486
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Saunders B. M.,
    2. Frank A. A.,
    3. Orme I. M.,
    4. Cooper A. M.
    Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection.Infect. Immun.68200033223326
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Soares M. B. P.,
    2. David J. R.,
    3. Titus R. G.
    An in vitro model for infection with Leishmania major that mimics the immune response in mice.Infect. Immun.65199728372845
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Taga T.,
    2. Kishimoto T.
    GP130 and the interleukin-6 family of cytokines.Annu. Rev. Immunol.151997797819
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Wang J.,
    2. Homer R. J.,
    3. Chen Q.,
    4. Elias J. A.
    Endogenous and exogenous IL-6 inhibit aeroallergen-induced Th2 inflammation.J. Immunol.165200040514061
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Yamamoto M.,
    2. Yoshikazi K.,
    3. Kishimoto T.,
    4. Ito H.
    IL-6 is required for the development of Th1 cell-mediated murine colitis.J. Immunol.164200048784882
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Interleukin-6 Deficiency Influences Cytokine Expression in Susceptible BALB Mice Infected with Leishmania major but Does Not Alter the Outcome of Disease
Richard G. Titus, Gregory K. DeKrey, Robin V. Morris, Milena B. P. Soares
Infection and Immunity Aug 2001, 69 (8) 5189-5192; DOI: 10.1128/IAI.69.8.5189-5192.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Interleukin-6 Deficiency Influences Cytokine Expression in Susceptible BALB Mice Infected with Leishmania major but Does Not Alter the Outcome of Disease
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Interleukin-6 Deficiency Influences Cytokine Expression in Susceptible BALB Mice Infected with Leishmania major but Does Not Alter the Outcome of Disease
Richard G. Titus, Gregory K. DeKrey, Robin V. Morris, Milena B. P. Soares
Infection and Immunity Aug 2001, 69 (8) 5189-5192; DOI: 10.1128/IAI.69.8.5189-5192.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • Notes
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

cytokines
Gene Expression Regulation
Interleukin-6
Leishmania major
Leishmaniasis, Cutaneous

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522